Baricitinib and ruxolitinib use through the UK HLH Network.

Holloway A, Gul D, Oppong AE, Alawad H, Rankin E, Steel M, Macleod J, Donaldson D, Qureshi I, Benham C, Chan XH, Faria R, Smith R, Pietsch D, Owen M, Jones A, Carpenter B, Laurence A, Tattersall RS, Manson JJ, Gohil SH

Open source

DOI: 10.1016/s2665-9913(26)00119-0
Published: 2026 Jul
Container: The Lancet. Rheumatology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2665-9913-26-00119-0,
  title = {Baricitinib and ruxolitinib use through the UK HLH Network.},
  author = {Holloway A and Gul D and Oppong AE and Alawad H and Rankin E and Steel M and Macleod J and Donaldson D and Qureshi I and Benham C and Chan XH and Faria R and Smith R and Pietsch D and Owen M and Jones A and Carpenter B and Laurence A and Tattersall RS and Manson JJ and Gohil SH},
  year = {2026},
  journal = {The Lancet. Rheumatology},
  doi = {10.1016/s2665-9913(26)00119-0},
  url = {https://doi.org/10.1016/s2665-9913(26)00119-0}
}

RIS

TY  - JOUR
TI  - Baricitinib and ruxolitinib use through the UK HLH Network.
AU  - Holloway A
AU  - Gul D
AU  - Oppong AE
AU  - Alawad H
AU  - Rankin E
AU  - Steel M
AU  - Macleod J
AU  - Donaldson D
AU  - Qureshi I
AU  - Benham C
AU  - Chan XH
AU  - Faria R
AU  - Smith R
AU  - Pietsch D
AU  - Owen M
AU  - Jones A
AU  - Carpenter B
AU  - Laurence A
AU  - Tattersall RS
AU  - Manson JJ
AU  - Gohil SH
PY  - 2026
JO  - The Lancet. Rheumatology
DO  - 10.1016/s2665-9913(26)00119-0
UR  - https://doi.org/10.1016/s2665-9913(26)00119-0
ER  -

APA

A, H., D, G., AE, O., H, A., E, R., M, S., J, M., D, D., I, Q., C, B., XH, C., R, F., R, S., D, P., M, O., A, J., B, C., A, L., RS, T., JJ, M., & SH, G. (2026). Baricitinib and ruxolitinib use through the UK HLH Network.. The Lancet. Rheumatology. https://doi.org/10.1016/s2665-9913(26)00119-0

Source records

pubmed · retrieved 2026-09-26T21:04:56.590Z